Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Schipani

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Journal of Antimicrobial Chemotherapy|October 14, 2017
Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modellingAdeniyi Olagunju, Alessandro Schipani, Oluseye Bolaji, et al.
Clinical Pharmacokinetics|September 24, 2014
Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapineAlessandro Schipani, David Back, Andrew Owen, et al.
Pharmacogenetics and Genomics|June 21, 2014
CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adultsAdeniyi Olagunju, Alessandro Schipani, Marco Siccardi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2012
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategiesAlessandro Schipani, Laura Dickinson, Marta Boffito, et al.
Chemmedchem|December 8, 2007
Lessons learnt from assembling screening libraries for drug discovery for neglected diseasesRuth Brenk, Alessandro Schipani, Daniel James, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse ModelYanmin Hu, Henry Pertinez, Fatima Ortega-Muro, et al.
Antiviral Therapy|April 6, 2012
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adultsAlessandro Schipani, Deirdre Egan, Laura Dickinson, et al.
Bioorganic & Medicinal Chemistry Letters|May 9, 2006
Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPaseOrla K Mc Carthy, Alessandro Schipani, Alex Musso Buendía, et al.
Bioorganic & Medicinal Chemistry|August 7, 2013
Investigation of acyclic uridine amide and 5'-amido nucleoside analogues as potential inhibitors of the Plasmodium falciparum dUTPaseShahienaz E Hampton, Alessandro Schipani, Cristina Bosch-Navarrete, et al.
British Journal of Clinical Pharmacology|November 28, 2015
A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and childrenAlessandro Schipani, Henry Pertinez, Rachel Mlota, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Journal of Antimicrobial Chemotherapy|October 14, 2017
Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modellingAdeniyi Olagunju, Alessandro Schipani, Oluseye Bolaji, et al.
Clinical Pharmacokinetics|September 24, 2014
Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapineAlessandro Schipani, David Back, Andrew Owen, et al.
Pharmacogenetics and Genomics|June 21, 2014
CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adultsAdeniyi Olagunju, Alessandro Schipani, Marco Siccardi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2012
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategiesAlessandro Schipani, Laura Dickinson, Marta Boffito, et al.
Chemmedchem|December 8, 2007
Lessons learnt from assembling screening libraries for drug discovery for neglected diseasesRuth Brenk, Alessandro Schipani, Daniel James, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse ModelYanmin Hu, Henry Pertinez, Fatima Ortega-Muro, et al.
Antiviral Therapy|April 6, 2012
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adultsAlessandro Schipani, Deirdre Egan, Laura Dickinson, et al.
Bioorganic & Medicinal Chemistry Letters|May 9, 2006
Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPaseOrla K Mc Carthy, Alessandro Schipani, Alex Musso Buendía, et al.
Bioorganic & Medicinal Chemistry|August 7, 2013
Investigation of acyclic uridine amide and 5'-amido nucleoside analogues as potential inhibitors of the Plasmodium falciparum dUTPaseShahienaz E Hampton, Alessandro Schipani, Cristina Bosch-Navarrete, et al.
British Journal of Clinical Pharmacology|November 28, 2015
A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and childrenAlessandro Schipani, Henry Pertinez, Rachel Mlota, et al.
Pageof 2